Oncology Corporate Profile
Cortice Biosciences is advancing the development of a novel class of taxoids, known as abeotaxanes, for potential treatment of a wide range of cancers and neurologic disorders. The company’s lead product candidate, TPI 287, has a number of advantages over existing taxane drugs, such as paclitaxel (Taxol® and Abraxane®) and docetaxel (Taxotere®), including the ability to penetrate the blood-brain barrier. This unique property enables the potential treatment of primary brain tumors and other cancers that spread to the brain, as well as non-cancer related diseases of the central nervous system.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|TPI-287||taxoid derivative||Brain Metastases||II|
|TPI-287||taxoid derivative||Glioblastoma Multiforme (GBM)||II|
|TPI-287 (+ radiotherapy)||taxoid derivative||Brain Metastases||I|